Pharmacogenetics of anticancer drugs in non-Hodgkin lymphomas

British Journal of Cancer

Volumn 85, Issue 10, 2001, Pages 1425-1431

  Loni, L ^a   Tacca, M Del ^a   Danesi, R ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Chemosensitivity; Drug resistance; Non Hodgkin lymphomas; Pharmacogenetics

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CAMPTOTHECIN; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; HYDROXYUREA; MELPHALAN; METHOTREXATE; MITOXANTRONE; PACLITAXEL; PREDNISONE; PROTEIN BCL 2; RAPAMYCIN; RETINOIC ACID; RITUXIMAB; TENIPOSIDE; TOPOTECAN; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CELL CYCLE; DRUG ACTIVITY; DRUG CHOICE; DRUG METABOLISM; DRUG SENSITIVITY; GENETIC ANALYSIS; HUMAN; MEDICAL DECISION MAKING; NONHODGKIN LYMPHOMA; ONCOGENE; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; DRUG RESISTANCE, NEOPLASM; LYMPHOMA, NON-HODGKIN; MODELS, BIOLOGICAL; MUTATION; ONCOGENE PROTEINS; PHARMACOGENETICS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 0035900796     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.2130     Document Type: Review

References (51)

1. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts
2. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia
3. Theophylline, Pentostatin (Nipent), and chlorambucil: A dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders
4. Azidothymidine resistance of H9 human T-cell lymphoma cells is associated with decreased sensitivity to antitumor agents and inhibition of apoptosis
5. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias
6. O6-alkylguanine-DNA alkyltransferase in cutaneous T-cell lymphoma: Implications for treatment with alkylating agents
7. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562
8. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents
9. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment
10. Role of p53 in cellular response to anticancer nucleoside analog-induced DNA damage
11. Current therapeutic paradigm for the treatment of non-Hodgkin's lymphoma
12. STAT signaling in the pathogenesis and treatment of cancer
13. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to campothecin
14. Fludarabine ability to down-regulate Bcl-2 gene product in CD5+leukaemic B cells: In vitro/in vivo correlations
15. Cancer surveillance series: Non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995
16. Bcl2 is the guardian of microtubule integrity
17. Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, Bcl-xl, NF-kappa B, and p53
18. Interactions between 2-fluoroadenine 9-beta-D-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells
19. p53 may mediate the mdr-1 expression via the WT1 gene in human vincristine-resistant leukemia/lymphoma cell lines
20. P53, MDM-2, BAX, and BCL-2 and drug resistance in chronic lymphocytic leukemia
21. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations with in vitro and in vivo chemoresponses
22. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapopotosis proteins in B-cell chronic lymphocytic leukemia
23. Changes in glucocorticoid-induced apoptosis and in expression of Bcl-2 protein during long-term culture of thymic lymphoma
24. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance
25. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis
26. Anaplastic large cell lymphoma of maternal origin involving the placenta: Case report and literature survey
27. Effect of fludarabine and arabinosylcytosine on multidrug resistant cells
28. Expression of Bcl-xl can confer a multidrug resistance phenotype
29. DNA-Dependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukemia lymphocytes to nitrogen mustards
30. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells
31. Expression of p53 predicts treatment failure in aggressive non-Hodgkin's lymphomas
32. Relationship between DNA cross-links, cell cycle and apoptosis in Burkitt's lymphoma cell lines differing in sensitivity to nitrogen mustard
33. Pleiotropic drug resistance in B-cell chronic lymphocytic leukemia-the role of Bcl-2 family dysregulation
34. Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines
35. Drug resistance mechanisms in chronic lymphocytic leukemia
36. Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan
37. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53
38. Bax-alpha promotes apoptosis induced by cancer chemotherapy and accelerates the activation of caspase 3-like cysteine proteases in p53 double mutant B lymphoma Namalwa cells
39. Constitutive overexpression of the cytidine deaminase gene confers resistance to cytosine arabinoside in vitro
40. Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs
41. Bcl-2 and Bcl-xl can differentially block chemotherapy-induced cell death
42. Retinoid-mediated inhibition of cell growth with stimulation of apoptosis in aggressive B-cell lymphomas
43. Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors
44. Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide
45. Drug resistance to DNA topoisomerase I and II inhibitors in human leukaemia, lymphoma, and multiple myeloma
46. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
47. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis
48. MDR1 and MPR expression in chronic B-cell lymphoproliferative disorders
49. Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: Presentation of a novel therapeutic paradigm
50. Increased sensitivity of hydroxyurea-resistant leukemic cells to gemcitabine
51. BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine